Ratings Humana AB

Equities

HUM

SE0008040653

Market Closed - Nasdaq Stockholm Other stock markets 11:29:46 2024-05-06 am EDT			5-day change	1st Jan Change
30.6 ^SEK	+4.08%		+4.08%	+8.70%

May. 06	Humana Names Successor to Outgoing President/CEO	MT
May. 06	Humana AB Announces CEO Changes	CI

Strengths

Its low valuation, with P/E ratio at 6.87 and 6.11 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.61 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The group shows a rather high level of debt in proportion to its EBITDA.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HUMANA AB	+8.70%	130M		B
BROOKDALE SENIOR LIVING INC.	+25.43%	1.45B		B
NATIONAL HEALTHCARE CORPORATION	+0.84%	1.41B	-	C+
AMVIS HOLDINGS, INC.	-28.45%	1.38B		-
SIENNA SENIOR LIVING INC.	+23.24%	751M	-	B
ARVIDA GROUP LIMITED	-7.27%	462M		B-
SONIDA SENIOR LIVING, INC.	+235.30%	439M	-	D+
MEDITERRANEAN TOWERS LTD.	-6.71%	337M	-	-
GOLDEN HOUSE LTD	+45.86%	96.03M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes